Immune dysregulation has been linked to occlusive vascular remodeling in pulmonary arterial hypertension (PAH) that is hereditary, idiopathic, or associated with other conditions. Circulating autoantibodies, lung perivascular lymphoid tissue, and elevated cytokines have been related to PAH pathogenesis but without a clear understanding of how these abnormalities are initiated, perpetuated, and connected in the progression of disease. We therefore set out to identify specific target antigens in PAH lung immune complexes as a starting point toward resolving these issues to better inform future application of immunomodulatory therapies.
, have been reported in patients with PAH.
The link between immunity and clinical PAH is also evident in experimental animal studies. For example, the athymic rat develops severe pulmonary hypertension attributed to a lack of regulatory T cells. 5 Production of pathological antibodies by bronchus-associated lymphoid tissue is observed in monocrotaline-induced pulmonary hypertension in rats. 6 However, specific target antigens in lung immune complexes have not been reported in either PAH or experimental pulmonary hypertension. This finding could provide mechanistic insight into factors that initiate and perpetuate immune dysregulation and their role in the pathophysiology of PAH.
METHODS
Expanded Materials and Methods are provided in the Online-Only Data Supplement.
Human Samples From Patients With PAH and Controls
All human samples used in this study were deidentified but had been obtained by written informed consent under protocols approved by the Administrative Panel on Human Subjects in Medical Research at the various sites described in the online-only Data Supplement. The demographic and other characteristics of patients with PAH and healthy controls used in the various studies are provided in Tables I and II in 
Lung Tissue
Lung tissues from patients with hereditary and idiopathic PAH and control subjects (unused donor lungs) were processed and stored as described previously. 7 
Cell Isolation and Culture
Pulmonary arterial endothelial cells (PAECs) 8 and PA smooth muscle cells (PASMCs) 9 from patients with PAH and donor control were harvested as described previously. In some experiments, we used commercially available PAECs. PAECs were cultured in EC media supplemented with 5% fetal bovine serum, EC growth supplement, and penicillin/streptomycin and used at passage 3 to 6. PASMCs were cultured in SMC media supplemented with 5% fetal bovine serum, SMC growth supplement, and gentamicin/amphotericin-B and used at passage 4 to 10. Induced pluripotent stem cells derived from fibroblasts and differentiated ECs were generated by previously published protocols. 8, 10 
Peripheral Blood Mononuclear Cells
Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll-Paque after centrifugation of whole blood at 400 g for 30 minutes. PBMCs (1x10 7 ) were used for further preparation of enriched monocytes. Cells that attached to wells after 2 hours represented an enriched monocyte preparation.
Clinical Perspective
What Is New?
• SAM domain and HD domain-containing protein 1 (SAMHD1) is an innate immune factor that suppresses HIV replication. We identified SAMHD1 immune complexes in lungs from patients with pulmonary arterial hypertension (PAH).
• Elevated SAMHD1 led to the discovery that human endogenous retrovirus (HERV-K) gene products, HERV-K envelope and deoxyuridine triphosphate nucleotidohydrolase (dUTPase), were elevated in lungs with PAH.
• Heightened expression of HERV-K dUTPase was observed in PAH circulating monocytes and induced pluripotent stem cells.
• Treatment with HERV-K dUTPase induced SAMHD1 and cytokines, including interleukin 6, in circulating monocytes and pulmonary arterial endothelial cells and promoted apoptosis in pulmonary arterial endothelial cells (PAECs).
• Rats treated with HERV-K dUTPase developed pulmonary hypertension.
What Are the Clinical Implications?
• Current treatments for PAH improve survival but are not disease modifying because they do not address the pathological mechanisms of inflammation and immune dysregulation.
• We show that perivascular immune complexes containing the antiviral protein SAMHD1 result from elevation in products of the endogenous retrovirus HERV-K that are expressed in PAH perivascular macrophages and circulating monocytes.
• The HERV-K dUTPase activates B cells, elevates cytokines in monocytes and pulmonary arterial endothelial cells, and increases pulmonary artery vulnerability to apoptosis, thus contributing to sustained inflammation, immune dysregulation, and progressive obliterative vascular remodeling.
• Mechanisms that normalize HERV-K expression could prevent and reverse PAH.
For detection of human endogenous retrovirus K deoxyuridine triphosphate nucleotidohydrolase (HERV-K dUTPase) in monocytes by quantitative polymerase chain reaction (PCR), we used the Pan Monocyte Isolation kit according to the manufacturer's protocol. PBMCs were cultured with RPMI-1640 and supplemented with 10% fetal bovine serum and penicillin/streptomycin.
HERV-K dUTPase Protein Purification
Recombinant HERV-K dUTPase protein was provided by Dr Ariza. The HERV-K gene encoding the dUTPase was cloned into the pTrcHis Topo TA expression vector, and the sequence was verified by DNA sequencing analysis as previously described. 11 The purity of the protein was assessed by SDS-PAGE and capillary-liquid chromatography nanospray tandem mass spectrometry performed at the Ohio State University Mass Spectrometry and Proteomics Facility.
11 High-purity dUTPase preparations, 11 free of contaminating DNA, RNA, lipopolysaccharide, and peptidoglycan, were used.
Treatment of Cells With HERV-K dUTPase Recombinant Protein or Lipopolysaccharide
PAECs (1x10 6 ), PBMCs (1x10 6 ), or enriched monocytes (isolated from 1x10 7 PBMCs as described earlier) were used. Cells were incubated with 0.1, 1.0, or 10 µg/mL of recombinant HERV-K dUTPase for 24 hours. Culture supernatants were collected for cytokine measurement by enzyme-linked immunosorbent assay (ELISA), and cell lysates were used for western immunoblotting. PBMCs were analyzed by single mass cytometry. PAECs were also assessed for apoptosis judged by heightened caspase activity during serum withdrawal 8 for 16 hours, when HERV-K dUTPase was added. PASMCs were assessed for proliferation (3-[4,5-Dimethylthiazol-2-Yl]-2,5-Diphenyltetrazolium Bromide [MTT] cell proliferation assay) in response to HERV-K dUTPase for 48 hours. In some experiments, IL6 neutralizing antibody versus isotype control was used to assess whether PAEC apoptosis induced by HERV-K dUTPase was IL6-dependent. In some experiments, monocytes and PAECs were treated with 1 µg/mL lipopolysaccharide for 6 hours, and cell lysates were used for quantitative PCR to assess HERV-K dUTPase mRNA.
Immunohistochemistry
Formaldehyde-fixed, paraffin-embedded tissue sections were deparrafinized and permeabilized with 0.2% Triton. Antigen retrieval was done with either citrate buffer pH 6.0 or 1 mM EDTA pH 8.0 depending on the primary antibodies. Sections were immersed in 0.3% hydrogen peroxide, blocked with 5% goat serum, and stained with primary antibodies. The following primary antibodies were used: SAMHD1 (1:500), CD3 (1:50), CD19 (1:100), plasma cell (1:100), follicular dendritic cell (1:50), and IL6 (1:1000). After incubation with secondary antibodies and amplification with streptavidin-biotin, sections were stained with 3,3-diaminobenzidine and counterstained with hematoxylin.
Immunofluorescent Staining
Tissue sections were processed as described earlier using primary antibodies for SAMHD1 (1:500), von Willebrand factor (1:1000), CD11c (1:100), CD68 (1:100), CD3 (1:50), HERV-K env (1:1000), HERV-K dUTPase (1:2000, provided by Dr. Ariza), and α-Actin (1:400), followed by fluorescent-conjugated secondary antibodies, Alexa Fluor 488 anti-mouse (1:800), or Alexa Fluor 594 anti-rabbit antibodies (1:800). Nuclei were stained with DAPI. Images were acquired using a FlouView 1000 or a Leica TCS SP8 confocal microscope.
In Situ SAMHD1 Antibody Production
To localize SAMHD1 antibody-producing cells, frozen lung tissues were fixed with acetone blocked with 5% normal goat serum and incubated with GST-tagged SAMHD1 recombinant protein in PBS (20 µg/mL) overnight at 4˚C. Sections were washed with PBS and incubated with FITC-conjugated anti-GST antibody (1:800) for 1 hour at room temperature. Nuclei were stained with DAPI. Images were acquired using a FlouView 1000 confocal microscope.
Immune Complex Immunoprecipitation and Mass Spectrometry to Identify Target Antigens
Immune complexes were captured using a Direct IP kit according to the manufacturer's protocol. The samples were then prepared using filter-aided sample preparation. 12 After a buffer exchange, digestion using trypsin was performed on the membrane filter overnight at 37˚C, where peptides were spun out, collected, and further cleaned on C18 reverse phase material and analyzed by liquid chromatography and mass spectrometry. The raw data were converted to .mgf format and searched by Byonic (Protein Metrics) using typical search conditions, and a 1% false discovery rate was determined using the standard reverse decoy strategy. Byonic output files were further analyzed using custom scripts developed in Matlab to aid in data visualization. We excluded proteins where we did not observe at least 3 peptides in at least 1 sample. Common contaminants were also excluded. For all other proteins, control and PAH patient data were assessed using significance analysis of microarrays to determine q values and a false discovery rate cutoff of 5%.
Quantification of SAMHD1-Specific Immune Complexes
Lung tissue (100 mg) was lysed using a dounce homogenizer and 500 µl of lysis buffer (0.025 mol/L Tris-HCl pH 7.5, 0.15 mol/L NaCl, 1 mM EDTA, 0.5% NP40, 5% glycerol) with proteinase/phosphatase inhibitors. After centrifugation at 20 000 g for 20 minutes at 4˚C, total protein concentration of the supernatant was measured and diluted in PBS to 1 µg/µl total protein. ELISA plates were coated with 0.02 mg/mL SAMHD1 antibody in PBS overnight at 4˚C. The plates were blocked with 5% BSA in PBS for 1 hour. Lung lysate was applied and incubated for 2 hours. HRP-conjugated species-specific anti-human IgG added to the plates and incubated for 1 hour at room temperature. Tetramethylbenzidine substrate was added for 15 minutes, the reaction was stopped with 2 N sulfuric acid, and optical density values were determined at 450 nm.
Western Immunoblotting
Lung lysates (50 mg) were prepared by homogenization with 500 µl of modified RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 1 mM PMSF) containing protease and phosphatase inhibitors. After centrifugation at 20 000 g for 20 minutes at 4˚C, the supernatant was collected. Protein concentration was determined by BCA. Equal amounts of protein were loaded on a precast NuPage 4% to 12% Bis-Tris gel and subjected to electrophoresis under reducing conditions and electrotransferred onto polyvinylidene difluoride membranes. After blocking with 5% milk in 0.5% Tween-PBS, membranes were incubated with primary antibodies against SAMHD1 (1:500), pSTAT3 (1:1000), STAT3 (1:1000), β-actin (1:10000), and α-tubulin (1:2000). Anti-mouse IgG secondary antibody (1:5000) was used. After incubation with HRP-conjugated secondary antibodies, signals were visualized with enhanced chemiluminescence or enhanced chemiluminescence prime.
Enzyme-Linked Immunosorbent Assay
Cytokine levels in human enriched monocytes, human PAECs, and rat lung lysates were measured using the Quantikine ELISA kit for human tumor necrosis factor α, IL1β, and IL6 and rat IL6 according to the manufacturer's protocol.
Quantitative PCR
Total RNA was extracted and purified from lung tissue or cells using spin column-based kits. Real-time PCR was performed according to the manufacturer's protocol. Quantitative PCR was performed with a 7900HT sequence-detection system or a CFX384 real-time system. Primers used were TaqMan gene expression assays, β-actin (Hs01060665_ g1), HERV-K(II) env (PN4441114, custom probe, Applied Biosystems), Syber Green assays, HERV-K dUTPase (Forward, 5'-AAATGGGCAACCATTGTCGGGAAACGAGC-3'; Reverse, 5'-TAGTACATAAATCTACTGCTGCACTGC-3), and β-actin (Forward, 5'-CATGCCATCCTGCGTCTGGA-3'; Reverse, 5'-CCGTGGCCATCTCTTGCTCG).
Unbiased Pan-Viral Metagenomic NextGeneration Sequencing
Samples were sequenced on an Illumina MiSeq instrument using 300/200 base pair (bp) paired-end sequencing. Approximately 18.3 million sequencing reads were analyzed using a modified version of SURPI (Sequence-Based UltraRapid Pathogen Identification), 13 a computational pipeline for the detection of microbes, including viruses, from nextgeneration sequencing data. Viral reads were identified as HERVs using a stringent edit distance requirement of 0 (no mismatches) across 75 bp of sequence. HERV reads were also taxonomically classified to the appropriate rank (family, genus, species, or subspecies/strain) by use of an in-house-developed classification algorithm using the SNAP nucleotide aligner (v0.15). 13 Heat maps were generated using matrix2png.
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Single Cell Mass Cytometry
PBMCs were stained with metal-conjugated antibodies and analyzed with a mass cytometer. 1x10 6 cells were used for each sample. Concatenated data were normalized using NormalizerR2013b and debarcoded using the Matlab DebarcoderR2013b. Gating was performed in http://nolanlab.cytobank.org. 15 The data were transformed to arcsinh values by taking the inverse hyperbolic sine of the raw data. The arcsinh ratio is the difference between the median arcsinh values of the 2 samples. Data from patients with PAH and controls are shown as arcsinh ratio normalized for assay control. Data for HERV-K dUTPase reflect treated over untreated (control) PBMCs (Stanford Blood Bank). Information about metal-conjugated antibodies is provided in the online-only Data Supplement.
Rat Model for the Induction of Pulmonary Hypertension by HERV-K dUTPase
The Animal Care Committee at Stanford University approved all experimental protocols used in this study after the published guidelines of the National Institutes of Health and the American Physiological Society. Adult male Sprague-Dawley rats (7 weeks, 180-200 g) were randomly assigned to a control or treatment group. Rats were either untreated or given a single subcutaneous dose of SU5416 (20 mg/kg body weight) 5 1 day before the first of 3 weekly intravenous injections of HERV-K dUTPase (0.2 mg/kg body weight) in saline. Rats in the control group were treated with saline vehicle. Twenty-one days after the first HERV-K dUTPase injection, cardiac function, right ventricular systolic pressure, and right ventricular hypertrophy were assessed as previously described. 7 Isoflurane anesthesia (1.5%, 1 L/min oxygen) was used during these procedures. Lung tissues were assessed by histology and ELISA. For histology, staining methods are described earlier. Quantification of muscularization and arterial number relative to alveoli was conducted in a blinded manner, and details are provided in the online-only Data Supplement. Images were acquired using a Leica DMLB microscope (Leica). For the measurement of IL6 by ELISA, 20 µg of lung tissue were homogenized. After centrifugation, the total protein concentration of the supernatant was measured and prepared in PBS at a concentration of 0.5 µg/µL.
Statistical Analysis
Data were analyzed using Prism 6.0 (GraphPad Software). Statistical significance was determined by 1-way ANOVA followed by Dunnett's or Tukey's test of multiple comparisons when >2 groups were being compared. When only 2 groups were compared, we used Student's t test. For some experiments, as indicated in the figure legends, we applied the Welch or Mann-Whitney test depending on the data distribution (ie, when the distribution was not normal we used the Mann-Whitney, and when the variance was unequal by F test we used the Welch). A P value of <0.05 was considered significant. Data are shown as mean±SEM or median, with interquartile range depending on the test applied. For target identification of immune complexes by mass spectrometry, significance analysis of microarrays was applied with false discovery rate cutoff of 5%. 16 For signaling data by single mass cytometry, Bonferroni-adjusted P value (P=7.14X10 
Accession Numbers
Next-generation sequencing data with human sequences removed, using BLASTn to the human genome at a lowstringency cutoff of 10 -5 , have been publicly deposited in the National Institutes of Health Sequence Read Archive (accession number SRP056561).
RESULTS
SAMHD1 Is a Target Antigen in Immune Complexes in PAH Lungs
We obtained lung tissues from unused donor lungs as controls and from patients with idiopathic or hereditary PAH (designated as PAH in the text) from the Pulmonary Hypertension Breakthrough Initiative Network. The characteristics of patients with PAH and controls are provided in Tables I and II in the online-only Data Supplement. To determine whether the target antigens of lung immune complexes differed in PAH versus control lungs, 3 PAH and 3 control lung samples were captured by complement 1q (C1q) immunoprecipitation, eluted, subjected to filter-aided sample preparation, 12 and analyzed by liquid chromatography tandem mass spectrometry. The top samples ranked based on q value and a false discovery rate <5% 16 are shown in Figure 1A . Of particular interest was SAMHD1, which was highly represented in PAH samples versus controls. SAMHD1 has been related to autoimmunity 18 and HIV infection, 19 conditions associated with PAH. We therefore expanded our analysis to a larger cohort of 16 PAH and 12 control lungs and confirmed a significant increase in the level of SAMHD1 immune complexes in the PAH lungs ( Figure 1B ). We next investigated the source of the SAMHD1 antibodies in lungs with PAH. Tertiary lymphoid tissue, which is associated with chronic inflammation and autoimmune diseases, 20 is particularly prominent in lungs with PAH. 3 We confirmed these findings ( Figure 1C and 1D) and investigated whether the tertiary lymph nodes are the source of SAMHD1 antibodies. After the addition of recombinant GST-tagged SAMHD1 protein to lung tissue sections and incubation of the tissue with an anti-GST-FITC-conjugated antibody, we observed SAMHD1 immunoreactive foci in the perivascular tertiary lymphoid tissue ( Figure 1E ), suggesting that these structures are the likely source of SAMHD1 antibody production.
Elevated SAMHD1 in Lung Cells With PAH and in Circulating Classical Dendritic Cells
In lungs with PAH, SAMHD1 immune complexes were associated with a heightened expression of SAMHD1 in lung lysates as assessed by western immunoblot (Figure 2A) . The site of increased expression of SAMHD1 in lungs with PAH was localized to the perivascular region as well as the vessel wall, whereas in control lungs, SAMHD1-positive cells were scattered in the lung parenchyma and excluded from the arterial walls ( Figure 2B ). To determine the cellular localization of SAMHD1, we performed confocal microscopy analysis in tissue sections double-immunolabeled with antibodies to SAM-HD1 and either von Willebrand factor to detect PAECs, CD68 as a marker of macrophages, CD11c for dendritic cells, and CD3 for T cells ( Figure 2C ). Almost all SAM-HD1-positive cells in the perivascular/vascular region coexpressed markers for macrophages, dendritic cells, and ECs, but not for T cells. The heightened expression of SAMHD1 in PAH was also confirmed in circulating classical dendritic cells ( Figure 2D , with details of gating in Figure IA in the online-only Data Supplement) assessed as part of a larger analysis applying single cell mass cytometry 15 to PBMCs.
HERV-K and Its Products HERV-K Envelope and dUTPase Are Increased in Idiopathic PAH
We next investigated whether SAMHD1 could be induced as an innate immune response 21 to an exogenous virus. In addition to HIV, 22 the Kaposi sarcoma virus (Human herpesvirus 8) 23 and hepatitis C virus 24 have been associated with PAH in some series but not others. 25 We therefore subjected flash-frozen lung tissue from 4 patients with PAH and 4 controls to a blinded unbiased metagenomic viral screen using the Illumina MiSeq next-generation sequencing platform and the SURPI computational pipeline to identify viral sequences. 13, 26 Consistent with a previous series, 25 we did not detect viruses previously implicated in PAH in our lung samples, nor did we detect other known exogenous viruses. However, we observed a significant increase in the percentage of human endogenous retroviral sequences in lung samples with PAH relative to controls, in particular HERV-K 27 family members ( Figure 3A) . The HERV-K family comprises <1% of the HERV sequences found in the human genome and is transcriptionally active. Although in theory an infectious virus could be produced, mutations interrupting the virus open reading frame lead to degenerate sequences, which makes this highly unlikely. However, the expression of HERV-K-encoded proteins has been shown to induce viral restriction pathways in early embryonic cells. 28 Furthermore, the increased expression of HERV proteins, including the envelope protein and the dUTPase, has been linked to cancer, 29 multiple sclerosis, 30 systemic lupus erythematosus, 31 and rheumatoid arthritis. 32 Also, the psoriasis susceptibility 1 locus, identified as the strongest genetic determinant of psoriasis, harbors a HERV-K that encodes for a dUTPase. 33, 34 We confirmed a significant induction in the HERV-K(II) envelope and HERV-K dUTPase mRNA in lungs with PAH versus controls (Figure 3B ). Confocal microscopy demonstrated that an increase in HERV-K envelope and dUTPase proteins were primarily present in perivascular CD68 + macrophages, which are abundant in lungs with PAH ( Figure 3C ). We further confirmed that circulating monocytes from patients with PAH exhibit higher mRNA levels of HERV-K dUTPase relative to control cells ( Figure 3D ).
HERV-K dUTPase Increases SAMHD1 and Cytokines in Enriched Monocytes and PAECs and Activates B Cells
The HERV-K dUTPase induces the secretion of Th1 and Th17 cytokines involved in the formation of psoriatic plaques, independent of its enzymatic activity, 11 thus associating HERV-K to the pathology of psoriasis. Having confirmed the higher HERV-K dUTPase in PAH lung macrophages and circulating monocytes ( Figure 3B through 3D), we determined whether recombinant HERV-K dUTPase could induce SAMHD1. Indeed, HERV-K dUTPase induces SAMHD1 in both enriched monocytes and PAECs ( Figure 4A and 4B) . Furthermore, in enriched monocytes, HERV-K dUTPase induces a profile of cytokines that are implicated in PAH, namely, tumor necrosis factor α, IL1β, and IL6 4 , ( Figure 4C ). We also observed induction of IL6 by HERV-K dUTPase in PAECs ( Figure 4D ). Moreover, we found that HERV-K dUTPase can activate B cells, as determined by CD69 expression ( Figure 4E , details of gating in Figure IB in the online-only Data Supplement), as well as STAT3 signaling ( Figure 4F ), consistent with a response related to the production of immunoglobulins. 35 Taken together, our observations related to the expansion of HERV-K and the sequelae of its dUTPase are consistent with chronic induction of inflammation and altered immunity observed in PAH.
HERV-K dUTPase Induces Apoptosis in PAECs
Because increased vulnerability to apoptosis is a feature of PAH PAECs, 8 we assessed the functional impact of HERV-K dUTPase on PAEC survival after serum withdrawal by the Caspase 3/7 assay. HERV-K dUTPase enhanced PAEC apoptosis after serum withdrawal ( Figure 5A ), as did coculture with HERV-K dUTPasetreated monocytes ( Figure IIA in the online-only Data Supplement). To determine whether the enhanced PAEC apoptosis was related to the induction of IL6, we pretreated the cells with an IL6-neutralizing antibody versus an isotype control ( Figure 5B ). We verified the suppression of PBMC pSTAT3 in response to IL6 by the neutralizing antibody as a measure of its efficacy ( Figure  IIB in the online-only Data Supplement), but we could not detect a significant impact of blocking IL6 on HERV-K-mediated enhanced PAEC apoptosis ( Figure 5B ). HERV-K dUTPase had no effect on PASMC proliferation assessed by 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay at 48 hours ( Figure IIC in the online-only Data Supplement).
HERV-K dUTPase Is Induced by Inflammatory Stimuli
Because circulating PAH monocytes have increased HERV-K dUTPase expression and are exposed to a highcytokine milieu, 4 we determined whether inflammatory stimuli that can be genotoxic 36 could upregulate HERV-K dUTPase mRNA. Indeed, lipopolysaccharide treatment increased HERV-K dUTPase in monocytes ( Figure 5C ) but not in PAECs ( Figure IID in the online-only Data Supplement). To determine whether the induction of HERV-K could be cell-specific, we also evaluated HERV-K dUTPase mRNA levels in induced pluripotent stem cells (iPSCs) because reprogramming of fibroblasts is known to induce an inflammatory response. 37 In fact, in a previous study, HERVs were transiently hyperactivated during reprogramming toward iPSCs and played an important role in this process. 38 However, once reprograming is complete and cells acquire full pluripotency, HERV activity decreases. 38 iPSCs from patients with PAH versus controls demonstrate higher HERV-K dUTPase mRNA Figure 4 Continued. ANOVA, analysis of variance; dUTPase, deoxyuridine triphosphate nucleotidohydrolase; HERV-K, human endogenous retrovirus K; HLADR, human leukocyte antigen-D related; IL, interleukin; pAKT, phospho-protein kinase B; PBMC, peripheral blood mononuclear cell; pERK, phospho-extracellular signal-regulated kinase; pMAPK, phospho-mitogen-activated protein kinase-activated protein kinase 2; pNFkB, phospho-nuclear factor kappa-light-chain-enhancer of activated B cells; pSTAT, phospho-signal transducer and activator of transcription; SAMHD1, SAM domain and HD domain-containing protein 1; TNF, tumor necrosis factor; and Veh, vehicle. levels ( Figure 5D ), suggesting that some intrinsic factor induces higher levels of HERV-K dUTPase mRNA in PAH cells responding to an environmental or genotoxic stress. Interestingly, the differentiated ECs did not show up-regulation of HERV-K dUTPase mRNA ( Figure IIE in the online-only Data Supplement). Further, no increase was discovered in HERV-K dUTPase mRNA in cultured PAH versus control PAECs ( Figure IIF in the online-only Data Supplement) or PASMCs ( Figure IIG in the onlineonly Data Supplement). This finding suggests that the propensity for HERV-K upregulation in response to an environmental stress is cell-specific.
HERV-K dUTPase Causes Pulmonary Hypertension in a Rat Model
To further substantiate a cause-and-effect relationship among HERV-K amplification, dUTPase production, and pulmonary hypertension, we delivered HERV-K dUTPase (0.2 mg/kg) by intravenous injection, once a week for 3 weeks, to adult male Sprague Dawley rats. Rats treated with HERV-K dUTPase exhibited decreased pulmonary artery acceleration time, increased right ventricular systolic blood pressure, and right ventricular hypertrophy (RVH) compared with saline-injected rats ( Figure 6A through 6C). These features were associated with adverse remodeling of the pulmonary circulation judged by increased muscularization of distal PAs ( Figure 6D ). Cardiac output, ejection fraction, and the number of vessels per 100 alveoli in the lung were not affected by HERV-K dUTPase treatment ( Figure III in the online-only Data Supplement). We further assessed the impact of HERV-K dUTPase in combination with the vascular endothelial growth factor receptor 2 blocker SU5416 (Sugen) on pulmonary hypertension in rats. 5 We observed that 3 weekly injections of HERV-K dUTPase with Sugen pretreatment resulted in increased pulmonary hypertension, as judged by a reduced pulmonary artery acceleration time, increased right ventricular systolic blood pressure and right ventricular hypertrophy, and muscularization of peripheral arteries when compared with SU5416 only-injected rats ( Figure 6A through 6D) .
HERV-K dUTPase induced IL6 in enriched monocytes and PAECs ( Figure 4C and D) . Heightened circulating levels of IL6 are observed in patients with PAH, 4 and a transgenic mouse with IL6 overexpression develops spontaneous pulmonary hypertension. 39 Indeed, rats injected intravenously with HERV-K dUTPase, with or without pretreatment with SU5416, exhibited increased IL6 by ELISA in lung tissue harvested from the rats at the A, PAECs were treated with 10 µg/mL HERV-K dUTPase, and apoptosis was assessed by Caspase-Glo 3/7 assay after overnight serum withdrawal (n=4). B, PAECs were pretreated with neutralizing IL6 antibody (IL6 Ab) or isotype control (Con) before HERV-K dUTPase treatment (n=4). C, HERV-K dUTPase mRNA by qPCR in monocytes stimulated with LPS 1µg/mL (n=3). D, HERV-K dUTPase mRNA by qPCR in iPSC from patients with PAH (n=7) and controls (n=7). Ranges represent mean±SEM. *P<0.05, ***P<0.001, ****P<0.0001 by Student's t test (A, C, and D) 
DISCUSSION
Several emerging therapies for PAH target the abnormal immune and inflammatory response linked to the pathology of PAH. 1 However, the key features that sustain immune dysregulation have not been elucidated. The identification of SAMHD1 led to the discovery of upregulation of the sequences encoding the retrovirus HERV-K and its product, dUTPase, in lungs with PAH, circulating monocytes, and iPSCs. Combined with the finding that the injection of HERV-K dUTPase induced pulmonary hypertension in a rat model, we propose that the activation of endogenous retrovirus sequences and expression of their gene products may underlie the chronic inflammatory and altered immune state associated with progressive vascular remodeling in PAH (see schema in Figure 7 ).
Diseases associated with HERV-K are complex diseases that probably represent the interaction of several factors, including genetic susceptibility as well as the microenvironment or location of cellular injury (eg, neuronal injury may lead to the expansion of HERVs in association with multiple sclerosis). 30 Morphea, also known as localized scleroderma, is linked to the local upregulation of HERVs in skin. 40 HIV is linked to PAH, 22 and the potential relationship between HIV as an activator of HERVs is well documented in previous studies. For example, HIV-1 Tat protein induces HERV-K mRNA, and HERV-K mRNA in PBMCs from HIV-1-infected patients is increased compared with HIV-negative controls. 41 Although the genes associated with HERV-K are present in all cell types, they may differ in expression levels perhaps because epigenetic features and mechanisms of RNA translation can be regulated by metabolism and the cellular microenvironment. 42 In tissues from patients with PAH, high levels of HERV-K expression in perivascular CD68+ cells may be sufficient to induce paracrine effects on vascular cells and B cells that promote PAH pathology.
Cells exposed to genotoxic agents that include oxidant stress, gamma irradiation, viruses, and cytokines show an increased expression of endogenous retroviruses. 43 Genomic instability is a feature of PAH, 44 attributed to impaired DNA repair in response to a genotoxic stress, 45 that could lead to unresolved cell-specific expansion of HERV-K and sustained immune dysregulation. Lipopolysaccharide upregulated HERV-K in monocytes, and it is an environmental stress that can be genotoxic. 36 Reprogramming in iPSCs, which is known to mediate an immune response, was linked to a PAHrelated increase in HERV-K. The mechanism causing the propensity for upregulation of HERV-K in certain PAH cell types would be interesting to investigate in future studies.
The expansion of HERV-K mRNA sequences has been related to both nuclear factor kappa-lightchain-enhancer of activated B cells (NFkB)-mediated transcription and a decrease in the methyltransferase SETDB1. 46 Enhanced HERV-K mRNA translation has also been described under conditions of cellular stress and is attributed to an increase in Staufin 1. Staufin 1 is a binding partner for HERV-K capsid protein, and when Staufin 1 is overexpressed, a rapid translation of HERV-K sequences occurs. Staufin 1 prevents eukaryotic initiation factor-α (EIF2α)-mediated stress granule formation, thereby facilitating mRNA translation under conditions of cellular stress. 47 This aberrant feature, impaired stress granule formation and heightened mRNA translation in response to inflammatory stress, was described by our group in PAECs with reduced bone morphogenetic protein receptor type 2, 7 owing to impaired phosphorylation of the EIF2α. It is therefore interesting that a mutation in a kinase that phosphorylates EIF2α, EIF2α kinase 4 (EIF2K4A, also known as GCN2), has been described in families with pulmonary veno-occlusive disease 48 and identified in some patients with hereditary PAH. 49 We demonstrated that HERV-K dUTPase activates monocytes, leading to an elevated production of cytokines (tumor necrosis factor α, IL6, and IL1β) and SAMHD1. HERV-K dUTPase activates B cells in a manner that could be responsible for the local production of SAMHD1 antibodies in tertiary lymphoid tissue in lungs with PAH. Although identification of the SAMHD1 antibodies led us to the identification of HERV-K, immune complexes and the activation of complement have also been linked to PAH. 50 However, we do not know whether SAMHD1 immune complexes have heightened immunogenicity. HERV-K dUTPase inoculation is sufficient to cause pulmonary hypertension in rats. Our model suggests a sustained effect of the dUTPase because IL6 was still elevated in the lung and localized to inflammatory and ECs 1 week after the third injection. Although a sustained elevation of IL6 levels could be responsible for pulmonary hypertension, as was seen in the transgenic IL6-overexpressing mouse, 39 other factors independent of IL6, such as those that control EC susceptibility to apoptosis, can also contribute to the pathology. It would be of interest to address the nature of endogenous retrovirus elements expressed in rodent models of pulmonary hypertension, but these elements are numerous, and a dUTPase with homology to HERV-K has not been identified. 51 Because of the complexity of human disease, it is difficult to prove a cause-and-effect relationship rather than an association between viral infection 23, 24 or endogenous retroviruses and PAH. A more comprehensive analysis of the mechanism of upregulation of retroviral sequences in PAH could lead to strategies to assess the impact of blocking the heightened production of these elements.
In summary, our findings show how upregulation of HERV-K could induce and perpetuate chronic immune dysfunction and inflammation and endothelial dysfunction, leading to adverse remodeling related to PAH. Circulation is available at http://circ.ahajournals.org.
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